New injection aims to tame rheumatoid arthritis

NCT ID NCT07230353

Recruiting now Disease control Sponsor: Xencor, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This early-stage trial is testing a new biologic drug called plamotamab in 68 adults with moderate to severe rheumatoid arthritis (RA) who haven't gotten enough relief from other treatments. The drug is given as a shot under the skin, and the main goal is to see if it's safe and tolerable. Researchers will also measure how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: plamotamab (a biologic drug given as an injection under the skin)
What this could lead to: If it works, this could point toward a new treatment option for people with rheumatoid arthritis who haven't responded well to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 68 participants, so it's primarily checking safety, not effectiveness. The drug may cause side effects or not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

rheumatoid arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RHEUMATOID ARTHRITIS

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Xencor Investigative Site
RECRUITING

Tbilisi, Georgia
Xencor Investigative Site
RECRUITING

Chisinau, Moldova
Xencor Investigative Site
RECRUITING

Auckland, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.